Takeda’s Ninlaro fails phase 3 amyloidosis trialTakeda is discontinuing a trial of its drug Ninlaro in systemic light-chain AL amyloidosis after it did not Share XTakeda’s Ninlaro fails phase 3 amyloidosis trialhttps://pharmaphorum.com/news/takedas-ninlaro-fails-phase-3-amyloidosis-trial/
Takeda to sell dry eye drug to Novartis for up to $5.3bnTakeda has announced it is to sell the dry eye drug Xiidra to Novartis, and a surgical patch Share XTakeda to sell dry eye drug to Novartis for up to $5.3bnhttps://pharmaphorum.com/news/takeda-to-sell-dry-eye-drug-to-novartis-for-up-to-5-3bn/
NICE backs interim funding for J&J/Takeda myeloma regimenA three-drug regimen for multiple myeloma based on Johnson & Johnson’s Darzalex, Takeda’s Velcade and dexamethasone will be Share XNICE backs interim funding for J&J/Takeda myeloma regimenhttps://pharmaphorum.com/news/nice-backs-interim-funding-for-jj-takeda-myeloma-regimen/
Takeda’s Entyvio outperforms AbbVie’s Humira in GI trialTakeda has announced results from its gastro drug Entyvio, showing that it largely outperformed the industry standard – Share XTakeda’s Entyvio outperforms AbbVie’s Humira in GI trialhttps://pharmaphorum.com/news/takedas-entyvio-outperforms-abbvies-humira-in-gi-trial/
Takeda mulling sale of emerging market drugs – reportTakeda could be considering selling some emerging-market drugs in a bid to cut debts following its merger with Share XTakeda mulling sale of emerging market drugs – reporthttps://pharmaphorum.com/news/takeda-could-sell-emerging-market-drugs/
Takeda’s Shire takeover could herald new era of pharma M&ATakeda has officially taken over Shire in a deal that could re-establish the trend for mega mergers in Share XTakeda’s Shire takeover could herald new era of pharma M&Ahttps://pharmaphorum.com/news/takedas-shire-takeover-could-herald-new-era-of-pharma-ma/
Takeda unlikely to sell OTC unit to pay Shire merger debtsTakeda’s $59 billion takeover of Shire is due to close tomorrow (Tuesday) and the company’s CEO Christophe Weber Share XTakeda unlikely to sell OTC unit to pay Shire merger debtshttps://pharmaphorum.com/news/takeda-unlikely-to-sell-otc-unit-to-pay-shire-merger-debts/
Takeda strikes three new immuno-oncology dealsTakeda is upping its commitment to cancer after its Shire takeover with the announcement of three new research Share XTakeda strikes three new immuno-oncology dealshttps://pharmaphorum.com/news/takeda-strikes-three-new-immuno-oncology-deals/
Eisai, Takeda and GARDP hunt for new antibioticsThe not-for-profit Global Antibiotic Research and Development Partnership has joined forces with Eisai and Takeda to search for Share XEisai, Takeda and GARDP hunt for new antibioticshttps://pharmaphorum.com/news/eisai-takeda-and-gardp-hunt-for-new-antibiotics/
